The Michael J. Fox Foundation has awarded a $1.5 million grant to Doylestown-based Kannalife Sciences, writes John George for the Philadelphia Business Journal.
This grant will support preclinical research on KLS-13019, a potential treatment for Parkinson’s disease.
Kannalife Sciences, based at the Pennsylvania Biotechnology Center, is developing small molecule therapeutics targeting inflammation.
The research will focus on KLS-13019’s effects on neuroinflammation and mitochondrial dysfunction, both critical factors in Parkinson’s disease.
Parkinson’s disease affects approximately 500,000 people in the U.S., causing neurodegenerative movement issues.
Michael J. Fox, diagnosed with early onset Parkinson’s in 1991, founded the Michael J. Fox Foundation in 2000, raising over $2 billion for Parkinson’s research.
Founded in 2010, Kannalife is a subsidiary of Neuropathix Inc. Their lead drug candidate, KLS-13019, is undergoing preclinical studies, aiming for FDA approval to treat chemotherapy-induced peripheral neuropathy.
Read more about the award to Kannalife Sciences in the Philadelphia Business Journal.
Exploring Neuroprotective Drugs with Dean Petkanas CEO of Kannalife Sciences
